Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2019-01-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 125.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 31 December 2018. It includes operating, investing, and financing cash flows, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The content is substantive financial data for a quarterly period, consistent with a comprehensive interim or quarterly financial report. The document length is 8484 characters, which is sufficient to contain actual financial data rather than just an announcement or certification. The presence of detailed financial statements and notes aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the appropriate classification is IR with high confidence. Q2 2019
2019-01-29 English
Quarterly Shareholder Update - December 2018 9 pages 383.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – December 2018' and dated 30 January 2019, indicating it is a quarterly update. It contains detailed discussion of drug development programs, clinical trial progress, sales figures for products, corporate updates including an investor research briefing and the 2018 Annual General Meeting, and key financial metrics for the quarter and half year ended 31 December 2018. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarterly and half-year figures) confirms this is a comprehensive interim financial report. It is not merely an announcement or a brief summary, but a detailed report with financial and operational information. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2019-01-29 English
Pharmaxis Announces LOXL2 Program Phase 2 Ready 2 pages 120.4KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 17 January 2019 from Pharmaxis announcing the readiness of their LOXL2 inhibitor program to enter phase 2 clinical studies following completion of toxicity studies. It discusses scientific and clinical development progress, potential partnerships, and forward-looking statements. There are no financial statements, regulatory filings, voting results, or management changes. The content is an announcement of a scientific and development milestone rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous company update, which corresponds to Regulatory Filings (RNS). The document length is about 5123 characters, which is not a brief announcement of a report publication but a substantive media release. However, it does not meet criteria for other specific categories such as Annual Report, Earnings Release, or Investor Presentation.
2019-01-16 English
PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA 1
Regulatory Filings Classification · 95% confidence The document is a media release announcing the resubmission of a New Drug Application (NDA) for Bronchitol to the FDA. It discusses regulatory and commercial milestones but does not contain financial statements, detailed financial performance, or comprehensive report data. The document is relatively short (4416 characters) and serves as an announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing in the sense of compliance documents or certifications, nor is it a management or investor presentation. The content is best classified as a general regulatory announcement or update about the company's drug approval process. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-12-19 English
Pharmaxis Announces First Relaunch Sales of Aridol in USA 2 pages 120.7KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing the first sales of a pharmaceutical product (Aridol) in the USA. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. It is a corporate announcement about product sales and FDA approval status. The document length is 5561 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement or corporate news release that does not fit other specific categories.
2018-12-12 English
Change in substantial holding 4 pages 253.4KB
Regulatory Filings
2018-11-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.